WallStreetZenWallStreetZen

NASDAQ: DMAC
Diamedica Therapeutics Inc Stock

$3.17+0.16 (+5.32%)
Updated May 16, 2024
DMAC Price
$3.17
Fair Value Price
$0.13
Market Cap
$120.35M
52 Week Low
$1.67
52 Week High
$4.75
P/E
-5.66x
P/B
2.6x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$19.27M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$20M
Beta
0.76
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

DMAC Overview

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DMAC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

DMAC ($3.17) is overvalued by 2,391.83% relative to our estimate of its Fair Value price of $0.13 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
DMAC ($3.17) is not significantly undervalued (2,391.83%) relative to our estimate of its Fair Value price of $0.13 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DMAC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DMAC due diligence checks available for Premium users.

Be the first to know about important DMAC news, forecast changes, insider trades & much more!

DMAC News

Valuation

DMAC fair value

Fair Value of DMAC stock based on Discounted Cash Flow (DCF)
Price
$3.17
Fair Value
$0.13
Overvalued by
2,391.83%
DMAC ($3.17) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DMAC ($3.17) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DMAC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

DMAC price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-5.66x
Industry
8.43x
Market
31.03x

DMAC price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.6x
Industry
6.06x
DMAC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

DMAC's financial health

Profit margin

Revenue
$0.0
Net Income
-$5.2M
Profit Margin
0%
DMAC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$49.3M
Liabilities
$2.9M
Debt to equity
0.06
DMAC's short-term assets ($47.48M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DMAC's short-term assets ($47.48M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DMAC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DMAC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$6.7M
Investing
$4.2M
Financing
-$1.0k
DMAC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

DMAC vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
DMAC$120.35M+5.32%-5.66x2.60x
CTXR$120.51M+6.72%-2.78x1.52x
NVCT$119.87M-1.80%-4.63x8.55x
CLRB$119.38M-0.89%-1.08x4.56x
VOR$122.87M+3.45%-1.02x1.00x

Diamedica Therapeutics Stock FAQ

What is Diamedica Therapeutics's quote symbol?

(NASDAQ: DMAC) Diamedica Therapeutics trades on the NASDAQ under the ticker symbol DMAC. Diamedica Therapeutics stock quotes can also be displayed as NASDAQ: DMAC.

If you're new to stock investing, here's how to buy Diamedica Therapeutics stock.

What is the 52 week high and low for Diamedica Therapeutics (NASDAQ: DMAC)?

(NASDAQ: DMAC) Diamedica Therapeutics's 52-week high was $4.75, and its 52-week low was $1.67. It is currently -33.26% from its 52-week high and 89.82% from its 52-week low.

How much is Diamedica Therapeutics stock worth today?

(NASDAQ: DMAC) Diamedica Therapeutics currently has 37,963,916 outstanding shares. With Diamedica Therapeutics stock trading at $3.17 per share, the total value of Diamedica Therapeutics stock (market capitalization) is $120.35M.

Diamedica Therapeutics stock was originally listed at a price of $3.49 in Dec 10, 2018. If you had invested in Diamedica Therapeutics stock at $3.49, your return over the last 5 years would have been -9.17%, for an annualized return of -1.91% (not including any dividends or dividend reinvestments).

How much is Diamedica Therapeutics's stock price per share?

(NASDAQ: DMAC) Diamedica Therapeutics stock price per share is $3.17 today (as of May 16, 2024).

What is Diamedica Therapeutics's Market Cap?

(NASDAQ: DMAC) Diamedica Therapeutics's market cap is $120.35M, as of May 18, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Diamedica Therapeutics's market cap is calculated by multiplying DMAC's current stock price of $3.17 by DMAC's total outstanding shares of 37,963,916.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.